Comparative Pharmacology
Head-to-head clinical analysis: DARVON N versus FYREMADEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON N versus FYREMADEL.
DARVON-N vs FYREMADEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak mu-opioid receptor agonist that produces analgesia by binding to opioid receptors in the central nervous system, altering the perception of and response to pain. Its metabolite norpropoxyphene has local anesthetic and sodium channel blocking effects, which may contribute to cardiac toxicity.
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
100 mg orally every 4 hours as needed for pain; maximum 600 mg per day.
100 mg orally twice daily.
None Documented
None Documented
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours. Accumulation of norpropoxyphene on repeated dosing increases risk of toxicity.
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Primarily renal (approximately 70% as unchanged drug and glucuronide conjugates); minor biliary/fecal elimination (25-30%).
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Category C
Category C
Opioid Analgesic
Opioid Analgesic